Literature DB >> 6376011

Effect of propranolol on delayed glucose recovery after insulin-induced hypoglycemia in normal and diabetic subjects.

J Kleinbaum, H Shamoon.   

Abstract

In order to evaluate the influence of beta-adrenergic blockade on recovery from insulin-induced hypoglycemia, we compared the effect of saline or propranolol infusion during concomitant hypoglycemia in normal and type I diabetic persons. The diabetic subjects were initially rendered euglycemic with a basal insulin infusion. Glucose turnover was measured using [3-3H]glucose tracer. Propranolol caused a small but significant delay in glucose recovery in normal subjects, with plasma glucose only 80% of the values seen during saline infusion 1 h after hypoglycemia (P less than 0.005). This delay was caused by a 70% reduction in the rebound glucose output, which was responsible for posthypoglycemic recovery. In the diabetic subjects, glucose recovery was significantly delayed as compared with that in normal persons, even in the absence of propranolol, and associated with reduced secretion of epinephrine and glucagon. Moreover, the addition of propranolol caused a further 50% reduction in glucose recovery such that plasma glucose remained below 50 mg/dl for 3 h. In contrast to normals, propranolol did not inhibit the already blunted rebound in glucose output. However, propranolol prevented the decline in glucose utilization that occurred when saline alone was infused. During saline infusion, glucose uptake was at basal rates by 60 min whereas, during propranolol administration, glucose uptake remained above baseline until 180 min (P less than 0.01). Thus, propranolol may interfere with glucose recovery after insulin-induced hypoglycemia in diabetic patients by blocking epinephrine's inhibition of glucose utilization whereas, in normals, propranolol's effect is largely accounted for by blockade of epinephrine-induced hepatic glucose production.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6376011     DOI: 10.2337/diacare.7.2.155

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  7 in total

1.  Insulin resistance in type 1 (insulin-dependent) diabetes following hypoglycaemia--evidence for the importance of beta-adrenergic stimulation.

Authors:  S Attvall; J Fowelin; H von Schenck; I Lager; U Smith
Journal:  Diabetologia       Date:  1987-09       Impact factor: 10.122

2.  Effect of oral verapamil on glibenclamide stimulated insulin secretion.

Authors:  C G Semple; C Omile; K D Buchanan; G H Beastall; K R Paterson
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

3.  Transient insulin resistance following infusion of adrenaline in type 1 (insulin-dependent) diabetes mellitus.

Authors:  M Kollind; U Adamson; P E Lins; B Hamberger
Journal:  Diabetologia       Date:  1988-08       Impact factor: 10.122

4.  Studies on the insulin-antagonistic effect of catecholamines in normal man. Evidence for the importance of beta 2-receptors.

Authors:  I Lager; S Attvall; B M Eriksson; H von Schenk; U Smith
Journal:  Diabetologia       Date:  1986-07       Impact factor: 10.122

5.  Early posthypoglycemic insulin resistance in man is mainly an effect of beta-adrenergic stimulation.

Authors:  S Attvall; B M Eriksson; J Fowelin; H von Schenck; I Lager; U Smith
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

6.  Withdrawal phenomena after atenolol and bopindolol: hormonal changes in normal volunteers.

Authors:  R J Walden; B Tomlinson; B Graham; C Smith; D J Betteridge; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

7.  Plasma Epinephrine Contributes to the Development of Experimental Hypoglycemia-Associated Autonomic Failure.

Authors:  Eric Lontchi-Yimagou; Sandra Aleksic; Raphael Hulkower; Rebekah Gospin; Akankasha Goyal; Bryan Kuo; William G Mitchell; Jee Young You; Laxmi Upadhyay; Michelle Carey; Oana A Sandu; Ilan Gabriely; Harry Shamoon; Meredith Hawkins
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.